Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zonisamide.

I E Leppik1

  • 1Department of Neurology, University of Minnesota, Minneapolis 55416, USA.

Epilepsia
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Zonisamide (ZNS) is an effective broad-spectrum antiepileptic drug for various epilepsy types. While generally safe with a favorable pharmacokinetic profile, its insolubility presents formulation challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Epilepsy & behavior : E&B·2012
Same author

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.

Journal of veterinary internal medicine·2012
Same author

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Clinical pharmacology and therapeutics·2012
Same author

Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.

Neurology·2010
Same author

Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.

Neurology·2008
Same author

Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.

Journal of veterinary pharmacology and therapeutics·2008
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Epileptology

Background:

  • Zonisamide (ZNS) is recognized as a broad-spectrum antiepileptic medication.
  • It demonstrates efficacy in both animal models and human patients experiencing epilepsy.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of Zonisamide (ZNS).
  • To identify optimal dosing and therapeutic blood levels for ZNS in epilepsy management.

Main Methods:

  • Review of existing data on ZNS efficacy across different epilepsy types.
  • Analysis of pharmacokinetic properties including half-life and protein binding.
  • Assessment of safety profile and potential adverse effects, including teratogenicity.

Main Results:

Related Experiment Videos

  • ZNS is effective for localization-related and generalized epilepsies, notably progressive myoclonic epilepsy.
  • Favorable pharmacokinetics include a long half-life and low protein binding.
  • Good safety profile noted, though animal model teratogenicity requires consideration.
  • Effective adult dosage: 400-600 mg/day, achieving blood levels of 20-30 mg/ml.

Conclusions:

  • Zonisamide is a potent antiepileptic drug with a wide range of applications.
  • Its pharmacokinetic and safety profiles are generally favorable, supporting its clinical use.
  • Challenges in parenteral formulation due to insolubility warrant further investigation.